Common targets, unfunded therapies: regulatory mapping and cost-utility of precision oncology for metastatic colorectal cancer in Brazil's public health system.
Precision cancer therapies exist for colorectal cancer but face funding barriers that prevent patients from accessing them.
The analysis mapped biomarker-directed colorectal cancer therapies and estimated their cost utility in Brazil. All evaluated precision-oncology pathways were interrupted before national access, and modeled regimens exceeded reference cost-effectiveness thresholds.
What the study was
- Study design
- Regulatory mapping and model-based cost-utility analysis
- Population
- Brazilian public health system patients with metastatic colorectal cancer
- Category
- Public Health
- Maturity
- Validated
- Journal
- Journal of cancer policy
Why it surfaced
The analysis provides actionable health-system evidence using regulatory sources and economic models, though results depend on modeling assumptions
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.